Transfusion-dependent beta-thalassemia

Hemoglobin, the molecule that carries oxygen inside red blood cells, is built from two alpha-globin chains and two beta-globin chains. Beta-thalassemia is an inherited condition in which the body makes too little beta-globin — one of those two halves.

A person has two beta-globin genes, one from each parent. One altered gene makes a carrier, a state called beta-thalassemia trait or minor, causing mild or no anemia. Two altered genes produce beta-thalassemia intermedia or major.

Beta-thalassemia major usually comes to attention between six and twenty-four months of age, and children then need regular red cell transfusions.

“Transfusion-dependent” describes how the illness behaves rather than naming a separate disease. The Thalassaemia International Federation defines it operationally as receiving six or more units of red cells over six months with a transfusion-free gap of six weeks or less, or frequent transfusions for more than a year. There is a counterpart — non-transfusion-dependent thalassemia — and people can move between the two categories over a lifetime.

It is inherited, and nothing a parent did or failed to do causes it. A child is born with it only by inheriting an altered gene from both parents. Where both parents carry beta-thalassemia major genes, there is a 1-in-4 chance for each pregnancy — a per-pregnancy chance, not a family quota.

The damage is a mismatch rather than only a shortage. Alpha chains keep being made at full rate with nothing to pair up with, and developing red cells die inside the marrow before they ever reach the bloodstream. The marrow then expands trying to compensate, which in untreated people causes changes to the bones of the face and skull and can push blood-forming tissue to grow outside the marrow.

Beta-thalassemia is more common in populations from the Mediterranean, the Middle East, Central and Southeast Asia and the Indian subcontinent — carrier states are frequent where malaria was historically endemic — and migration has since made it a worldwide condition.

Untreated, the anemia dominates: severe tiredness, weakness, breathlessness, palpitations, pale skin, poor weight gain and stunted growth in a child, jaundice, gallstones, an enlarged liver and spleen.

With regular transfusion the anemia is controlled — and the long-term problem becomes iron. This is the single most important structural fact about the disease, and everything else follows from it.

A unit of transfused red cells brings roughly 200 mg of iron with it, and the human body has no mechanism for excreting excess iron. It simply accumulates, because there is nowhere for it to go. On recommended transfusion schedules that works out to somewhere around 0.32 to 0.64 mg of iron per kilogram of body weight per day.

The iron deposits in the heart, liver, pituitary gland and pancreas, and over years it causes heart failure, liver scarring and cancer, growth problems and a range of hormone deficiencies. Without iron removal, heart muscle damage has historically caused heart failure as early as the second decade of life.

The crucial thing is that this is preventable rather than inevitable — iron can be removed. It is also why removal starts early and continues, because once iron has been deposited in some tissues the damage is often permanent.

The backbone is regular red cell transfusion, generally every two to four weeks, aimed at keeping hemoglobin above a target level before each transfusion and below a ceiling afterward.

Alongside it runs iron chelation — medicine that binds iron so the body can get rid of it. There are three licensed drugs and they differ enormously in what they ask of a person’s life: deferoxamine as an infusion over eight to twelve hours, five or six nights a week, and two oral options, deferiprone three times a day and deferasirox once a day.

Chelation usually starts after the first ten to twenty transfusions or once a blood measure called ferritin rises above a threshold, and the effect is tracked with a particular kind of MRI scan that measures how much iron is actually in the liver, rather than relying on blood tests alone.

An allogeneic transplant — replacing the marrow with a donor’s — is an established option, and age matters for it. EBMT has identified fourteen as the oldest age for best outcome in transplant for this condition, while registry data from the US supported optimal outcomes up to age seven.

Two gene therapies are approved: betibeglogene autotemcel (Zynteglo), which adds a working beta-globin gene, and exagamglogene autotemcel (Casgevy). Both use the person’s own blood stem cells, edited in a laboratory and given back, so no donor is involved — but both still require full conditioning chemotherapy to empty the marrow first, and the same hospital course as a transplant.

The defining experience is rhythm rather than crisis. A transfusion every two to four weeks for life, chelation on most or all days, scans, clinic reviews. It is a life with a schedule attached — and it is a life, not a holding pattern while something better is arranged.

The NHS puts it plainly on outlook: with current treatments, people are likely to live into their fifties, sixties and beyond. TIF is equally honest about what that improvement brought with it — living longer allowed problems that were never seen before to appear, in hormones, heart, liver and bone, over decades.

Chelation is genuinely hard to sustain, and it is worth saying that this is a feature of the treatment rather than a failing of the person taking it. An eight-to-twelve-hour infusion five or six nights a week is a great deal to ask of anybody, and the arrival of tablets changed daily life for many people.

Families carry tissue typing as an event of its own. A sibling who matches may be asked to donate; a sibling who does not match may feel that too. Parents are asked to weigh a stable, known life against a defined window of serious risk — conditioning chemotherapy, a long stretch of very low blood counts, infection, possible infertility, and, with a donor transplant, graft-versus-host disease.

Family donors dominate. TIF’s guidance is that a transplant should be offered early, before complications from iron overload develop, if an HLA-identical donor is available — and the HLA-identical sibling is the long-established route.

Unlike some inherited conditions, though, an unrelated donor here is not a fallback of last resort. The EBMT Handbook states that matched unrelated transplantation should be considered a standard option alongside related transplantation, with comparable outcomes in recent real-world data, provided the match is close across both classes of tissue-type marker.

Most people with transfusion-dependent thalassemia do not have an HLA-identical sibling. For them the routes are an unrelated donor, a half-matched relative in a specialist centre or trial, or — where it is approved and funded — gene therapy.

There is a genuine reason registry representation matters for this condition specifically. Thalassemia is concentrated in populations of Mediterranean, Middle Eastern, South Asian and Southeast Asian ancestry, and tissue types track ancestry. Whether an unrelated match exists therefore depends on how many people from exactly those communities have joined a registry.